ADB-HEXINACA

ADB-HEXINACA
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B; US: Schedule I;
Identifiers
	IUPAC name N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-hexyl-1H-indazole-3-carboxamide;
CAS Number	3047777-38-5 ;
PubChem CID	163191674;
ChemSpider	109107958;
CompTox Dashboard (EPA)	DTXSID701038279 ;
Chemical and physical data
Formula	C20H30N4O2
Molar mass	358.486 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@@H](C(C)(C)C)C(N)=O)C1=NN(CCCCCC)C2=C1C=CC=C2;
	InChI InChI=1S/C20H30N4O2/c1-5-6-7-10-13-24-15-12-9-8-11-14(15)16(23-24)19(26)22-17(18(21)25)20(2,3)4/h8-9,11-12,17H,5-7,10,13H2,1-4H3,(H2,21,25)(H,22,26)/t17-/m1/s1; Key:PZMLDAGKYPJWHJ-QGZVFWFLSA-N;

ADB-HEXINACA (also known as ADB-HINACA and ADMB-HEXINACA) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a longer chain homologue of previously encountered synthetic cannabinoid compounds such as ADB-BUTINACA and ADB-PINACA.^[1]^[2] The pharmacology of ADB-HEXINACA and numerous analogues at CB1 and CB2 receptors has been reported.^[3]

Quick Facts Legal status, Identifiers ...

[1]

[2]

[3]

ADB-HEXINACA

See also

References

Wikiwand - on